ClinicalTrials.gg
TerminatedNCT02093962Updated May 16, 2025Results posted

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

A Phase 2 interventional study of TH-302 combination with pemetrexed and Matched placebo in combination with pemetrexed in Non-small Cell Lung Cancer, sponsored by ImmunoGenesis. Terminated at 80 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by ImmunoGenesis · Phase 2, Interventional, and Treatment

Why this study was terminated
At the interim analysis, the futility boundary was not met and the study was stopped due to insufficient efficacy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
37th of 223
265 · median 64
Started
2014
with 4 others
Phase 2
128 of 227
12 open now
Registered
139th of 227
by date

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 37th largest by enrollment of the 223 interventional ones that give a count, is one of 5 that started in 2014, is one of 128 in phase 2, and was the 139th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether TH-302 in combination with pemetrexed is safe and effective in the treatment of non-squamous non-small cell lung cancer.

Read the detailed description

TH-302 is designed to target the hypoxic regions of tumors which are generally located distant from tumor vessels. Pemetrexed has poor tissue penetration and targets the regions of tumors that are located in proximity to the tumor vessels. The presence of hypoxia in solid tumors is associated with a more malignant phenotype and resistance to chemotherapy. The hypoxia-activated prodrug, TH-302, is designed to selectively target the hypoxic microenvironment. There is evidence supporting the presence of hypoxia in NSCLC lesions based on a hypoxia PET study. Combining pemetrexed with TH-302 may enable the targeting of both the normoxic and hypoxic regions of NSCLC lesions.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • TH-302
  • TH-CR-415
  • Pemetrexed
  • Non-small cell lung cancer
  • Lung cancer
  • Evofosfamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age.
  • or cytologically confirmed stage IIIB or IV NSCLC with non-squamous histology
  • Recurrent or progressive disease after one prior platinum-based non-pemetrexed chemotherapy treatment for advanced disease with or without maintenance
  • /adjuvant cytotoxic chemotherapy initiated \< 12 months prior to study randomization will be counted as one prior treatment
  • Neoadjuvant/adjuvant cytotoxic chemotherapy initiated ≥ 12 months prior to study randomization will not be counted as one prior chemotherapy treatment
  • Use of targeted agents (e.g., monoclonal antibodies or kinase inhibitors) will not be counted as a prior chemotherapy treatment
  • Patients with known EGFR-activating mutations or ALK rearrangements should have received treatment with a targeted kinase inhibitor (e.g., erlotinib, crizotinib) and no longer be considered as a candidate for such treatment
  • according to 1.1
  • performance status 0-1
  • Resolution to Grade ≤ 1 Adverse Events, of all toxic effects of prior therapy
  • Adequate hematologic, hepatic, cardiac, and renal function
  • Female patients of must have a negative serum or urine pregnancy test, whichever is considered standard by the institution

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of small cell carcinoma of the lung, squamous cell carcinoma of the lung or NSCLC NOS
  • Prior therapy with pemetrexed
  • Inability or unwillingness to take folic acid, vitamin B12 supplementation or
  • Inability to discontinue non-steroidal anti-inflammatory drugs for 5 days (long half-life) or for 2 days (short half-life, if CrCL \<80 mL/min) before pemetrexed dosing and until 2 days after pemetrexed dosing
  • or any untreated or symptomatic , unless the following criteria are met:

    • brain metastases are stable and have been previously treated with either whole-brain radiotherapy or gamma-knife surgery
    • steroids are currently not required and more than 14 days since last steroid treatment
  • Symptomatic pleural effusion (> Grade 1 dyspnea) that is not amenable to drainage
  • Treatment with other systemic anticancer therapy within 4 weeks prior to the first dose of study medication
  • Treatment with full field radiation therapy within 4 weeks or limited field radiation therapy within 2 weeks prior to the first dose of study medication
  • Major surgery within 4 weeks or minor surgery within 2 weeks prior the first dose of study medication
  • Elective or a planned major surgery while on study treatment
  • Radiation therapy to greater than 25% of the bone marrow
  • active infection (e.g. tuberculosis, viral hepatitis, )
  • Any other serious uncontrolled medical disorders or psychological conditions that may interfere with study conduct
  • Concurrent active other than adequately treated basal cell or squamous cell carcinoma of the skin or pre-invasive carcinoma of the cervix.
  • Pregnant or breast feeding
  • Patients who are taking medications that prolong and have a risk of Torsades de Pointes (Appendix F) or who have a history of long QT syndrome
  • Patients who are taking medications that are strong inducers or inhibitors of
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
265 participants (actual)

Study arms

  • Experimental
    TH-302 and pemetrexed

    TH-302 in combination with pemetrexed

    Drug: TH-302 combination with pemetrexed

  • Active comparator
    Placebo and pemetrexed

    Matching placebo in combination with pemetrexed

    Drug: Matched placebo in combination with pemetrexed

Interventions

  • DrugTH-302 combination with pemetrexed

    Drug pages: TH 302 · Pemetrexed

    400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle. Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration.

  • DrugMatched placebo in combination with pemetrexed

    Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle. Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    To assess the efficacy of pemetrexed in combination with TH-302 as determined by overall survival in patients with advanced non-squamous NSCLC in the second-line chemotherapy setting compared with pemetrexed in combination with placebo

    Time frame: 2 years

07

Results

Posted Aug 11, 2017

Participant flow

Participant flow — Overall Study
MilestoneTH-302 and PemetrexedPlacebo and Pemetrexed
Started134131
Received treatment130130
Completed00
Not completed134131

Outcome measures

PrimaryOverall Survival

To assess the efficacy of pemetrexed in combination with TH-302 as determined by overall survival in patients with advanced non-squamous NSCLC in the second-line chemotherapy setting compared with pemetrexed in combination with placebo

Time frame:
2 years
Reported as:
Count of participants · Participants
Overall Survival
ParticipantsTH-302 and PemetrexedPlacebo and Pemetrexed
Overall Survival5149

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TH-302 and Pemetrexed—52/130 (40%)130/130 (100%)
Placebo and Pemetrexed—72/130 (55.4%)130/130 (100%)
Most frequent serious events
Showing 10 of 73
Most frequent serious events
EventTH-302 and PemetrexedPlacebo and Pemetrexed
AnaemiaBlood and lymphatic system disorders1/1307/130
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/1303/130
PneumoniaInfections and infestations2/1304/130
Respiratory failureRespiratory, thoracic and mediastinal disorders0/1304/130
OverdoseInjury, poisoning and procedural complications0/1304/130
Respiratory tract infectionInfections and infestations1/1303/130
ThrombocytopeniaBlood and lymphatic system disorders2/1303/130
DyspnoeaRespiratory, thoracic and mediastinal disorders3/1302/130
ErysipelasInfections and infestations2/1301/130
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/1302/130
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTH-302 and PemetrexedPlacebo and Pemetrexed
AnaemiaBlood and lymphatic system disorders40/13050/130
NauseaGastrointestinal disorders37/13040/130
FatigueGeneral disorders25/13033/130
NeutropeniaBlood and lymphatic system disorders24/13030/130
AstheniaGeneral disorders19/13028/130
ThrombocytopeniaBlood and lymphatic system disorders10/13025/130
VomitingGastrointestinal disorders17/13025/130
StomatitisGastrointestinal disorders18/13024/130
DiarrhoeaGastrointestinal disorders16/13023/130
Decreased appetiteMetabolism and nutrition disorders20/13017/130

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TH-302 and PemetrexedPlacebo and PemetrexedTotal
<=18 years000
Between 18 and 65 years8185166
>=65 years534699
Sex: Female, Male
Sex: Female, Male(Participants)TH-302 and PemetrexedPlacebo and PemetrexedTotal
Female5857115
Male7674150
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TH-302 and PemetrexedPlacebo and PemetrexedTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander112
Black or African American336
White130126256
More than one race000
Unknown or Not Reported011
08

Study locations

80 sites
  • UAB Cancer Center
    Birmingham, Alabama 35294, United States
  • Ironwood Cancer and Research Centers
    Chandler, Arizona 85224, United States
  • California Cancer Center
    Encinitas, California 92024, United States
  • California Cancer Center Associates
    Fresno, California 93720, United States
  • UCLA-Department of Medicine a Division of Hem/Onc
    Los Angeles, California 90095, United States
  • Sarcoma Oncology Research Center
    Santa Monica, California 90403, United States
  • VA Eastern Colorado Healthcare System
    Denver, Colorado 80220, United States
  • Christiana Care Health Services
    Newark, Delaware 19713, United States
  • Cancer Specialists of North Florida - CBO
    Jacksonville Beach, Florida 32256, United States
  • AMPM Research
    Miami, Florida 33133, United States
  • Research Medical Center
    Kansas City, Kansas 64132, United States
  • Ochsner Clinical Foundation
    New Orleans, Louisiana 70121, United States
  • Walter Reed National Military Medical Center
    Bethesda, Maryland 20889, United States
  • St. Joseph Mercy Ann Arbor Cancer Center
    Ann Arbor, Michigan 48106, United States
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
  • Montefire-Einstein Center for Cancer Care
    Bronx, New York 10461, United States
  • Clinical Research Alliance
    New York, New York 10021, United States
  • Durham VA Medical Center
    Durham, North Carolina 27705, United States
  • W.G. (Bill) Hefner VA Medical Center
    Salisbury, North Carolina 28144, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • DORN VA Medical Center
    Columbia, South Carolina 29209, United States
  • Regional Cancer Care Institute at Regional Health
    Rapid City, South Dakota 57701, United States
  • Associates in Oncology & Hematology
    Chattanooga, Tennessee 37421, United States
  • San Antonio Military Medical Center
    Fort Sam Houston, Texas 78234, United States
  • Oncology Consultants
    Houston, Texas 77024, United States
  • Millennium Oncology
    Houston, Texas 77090, United States
  • Fpr Belvoir Community Hospital
    Fort Belvoir, Virginia 22060, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Hospital Na Bulovce, Department of Pneumology and Thoracic Surgery
    Liben, 18081, Czechia
  • General Univesity Hospital in Prague, Clinic of Oncology
    Prague, 12800, Czechia
  • Thomayer Hospital, Clinic of Pneumology
    Praha 4, 140 59, Czechia
  • Regional Hospital T. Bta, Department of Pneumology
    Zlin, 76275, Czechia
  • Asklepios Fachkliniken Munchen-Gaunting
    Gauting, Bavaria 82131, Germany
  • Marien Hospital Herne
    Herne, North Rhine-Westphalia, Germany
  • Charité Universitätsmedizin Berlin;
    Berlin, 12200, Germany
  • Klinikum Frankfurt Höchst GmbH
    Frankfurt, 65929, Germany
  • Lungen Clinic Grosshandsdorf GmbH
    Grosshansdorf, 22927, Germany
  • Universitatsklinikum Schleswig-Holstein
    Lubeck, 23538, Germany
  • Städtisches Klinikum München - Klinikum Bogenhausen
    München, 81925, Germany
  • Universitätsklinikum Ulm; Zentrum für Innere Medizin
    Ulm, 89081, Germany
  • IASO General, Oncology Unit
    Athens, 15562, Greece
  • Attikon University General Hospital
    Athens, Greece
  • Department of Medical Oncology
    Heraklion, 71110, Greece
  • University General Hospital of Patras, Oncology Unit
    Patras, 26500, Greece
  • Koranyi National Institute of TBC and Pulmonology, 14th Dept of Pulmonology
    Budapest, 1121, Hungary
  • Koranyi National Institute of TBC and Pulmonology, 6th Department of Pulmonology
    Budapest, 1121, Hungary
  • Koranyi National Institute of TBC and Pulmonology, 8th Department of Pulmonology
    Budapest, 1121, Hungary
  • University of Debrecen, Medical and Health Science Center, Department of Pulmonology
    Debrecen, 4032, Hungary
  • Csongrad County Hospital of Chest Diseases
    Deszk, 6772, Hungary
  • Hetenyi Geza Hospital, Department of Oncology
    Szolnok, 5004, Hungary
  • "Mater Salutis" Hospital - Operative Unit of Oncology
    Verona, Legnago 37045, Italy
  • A.O.U.S. Luigi GonzagaUniversity Hospital
    Orbassano, Torino 10043, Italy
  • Hospital Bellaria "Carlo Alberto Pizzardi" - Operative Unit of Oncology
    Bologna, 40139, Italy
  • IRCCS Azienda Ospedallera Universitaria San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro
    Genova, Italy
  • European Institute of Oncology (IEO) - Medical Care Unit
    Milan, 20141, Italy
  • S. Gerardo Hospital - Complex Structure of Medical Oncology
    Monza, 20900, Italy
  • Azienda Ospedaliera Universitaria Policlinico della Seconda Universita di Napoli
    Napoli, Italy
  • University Hospital of Pisa, Department of Cardothoracic Surgery, Operative unit of Pneumology
    Pisa, 56124, Italy
  • "Santa Maria degli Angeli" - Hospital - Complex Operative Unit of Oncology
    Pordenone, 33170, Italy
  • San Camillo-Forlanini Hospital - U.O.C. Pneumologia Oncologica 1
    Rome, 00152, Italy
  • Med-Polonia Sp. z o.o.
    Poznan, 60693, Poland
  • L. Rydygier Provencial Hospitals in Torun, Dept. of Tumors Chemotherapy
    Torun, 87-100, Poland
  • Maria Sklodowska-Curie Institute of Oncology in Warsaw
    Warsaw, 02781, Poland
  • Oncology Centre "Sf. Nectarie"
    Craiova, Dolj County, Romania
  • Pro. Dr. Alex Trestioreanu Institute of Oncology
    Bucharest, 022328, Romania
  • Prof. Dr. Ioan Chiricuta Institute of Oncology
    Cluj-Napoca, 400015, Romania
  • Republican Clinical Oncology Center under the Ministry of Healthcare of Tatarstan Republic
    Kazan, Republic Of Tatarstan 420029, Russian Federation
  • Russian Oncology Research Center n.a. N.N. Blokhin under the Russian Academy of Medical Sciences
    Moscow, 115478, Russian Federation
  • Blokhin Russian Oncology Research Center
    Moscow, 15478, Russian Federation
  • State Healthcare Institution: Nizhny Novgorod Regional Oncology Center
    Nizhny Novgorod, 603081, Russian Federation
  • St. Petersburg Clinical Center for Applied Special Medical Services (Oncology)
    St. Petersburg, 194044, Russian Federation
  • St. Petersburg 1st State Medical University n.a.I.P. Pavlov under the Ministry of Healthcare of the Russian Federation
    St. Petersburg, 197101, Russian Federation
  • City Clinical Oncology Center, Oncology Department (Thoracic Oncology)
    St. Petersburg, 198255, Russian Federation
  • General University Hospital Gregorio Maranon, Dept. of Oncology
    Madrid, 28007, Spain
  • Jimenez Diaz Foundation
    Madrid, 28040, Spain
  • Hospital Universitario Puerta de Hierro
    Madrid, 28222, Spain
  • University Hospital Virgen de Valme
    Sevilla, 41014, Spain
  • Dr. Peset University Hospital, Dept. of Oncology
    Valencia, 46017, Spain
  • Hospital Universitario La Fe, Servicio de Oncologia
    Valencia, 46026, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Apr 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2014
First posted
Mar 21, 2014
Start
Jun 2014
Primary completionActual
Apr 2016
CompletionActual
May 2016
Results first posted
Aug 11, 2017
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02093962
Lead sponsor
ImmunoGenesis
Collaborators
EMD Serono
Responsible party
Sponsor
First posted
Mar 21, 2014
Start date
Jun 2014
Primary completion
Apr 2016
Completion
May 2016
Results posted
Aug 11, 2017
Last update
May 16, 2025

Study contacts

Tillman Pearce, MD
study chair · Threshold Pharmaceuticals
Jonathan Goldman, MD
principal investigator · UCLA-Dept of Medicine a Div of Hem/Onc

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: TH 302 · Pemetrexed

Start the discussion